# Identification of Ferroptosis‐Related Hub Genes and Immune Infiltration Landscape in Chronic Kidney Disease via Bioinformatics and Experimental Verification

**Authors:** Yong Luo, Zhong‐ying Huang, Ji‐fang Yang

PMC · DOI: 10.1002/iid3.70391 · Immunity, Inflammation and Disease · 2026-02-25

## TL;DR

This study identifies key genes linked to ferroptosis in chronic kidney disease and explores immune cell changes, offering potential new targets for diagnosis and treatment.

## Contribution

The study introduces a novel combination of bioinformatics and experimental validation to identify ferroptosis-related hub genes in CKD.

## Key findings

- Seven hub genes (NNMT, GDF15, etc.) were identified and validated as upregulated in CKD.
- Hub genes are linked to immune dysfunction and disease progression through specific biological pathways.
- In vitro experiments confirmed increased expression of NFE2L2, NNMT, and GDF15 in CKD-related cell models.

## Abstract

Chronic kidney disease (CKD) is a serious global health problem with increasing incidence. Ferroptosis plays a crucial role in kidney diseases, but limited studies have elucidated the mechanism and role of ferroptosis in CKD.

CKD data sets and ferroptosis‐related genes were acquired from the Gene Expression Omnibus (GEO) database and FerrDB V2. By integrating bioinformatics including weighted gene coexpression network analysis (WGCNA), enrichment analyses, protein‐protein interaction (PPI) network and GeneMANIA analysis, ferroptosis‐related hub genes were identified in CKD. Validation of hub genes was conducted using an external data set, and diagnostic potential capability was evaluated through receiver operating curve (ROC) analysis. Subsequently, the relationship between hub genes and clinical traits was performed using Nephroseq v5 database. Gene set enrichment analysis (GSEA) of hub genes was performed. The CIBERSORT algorithm was employed to examine the infiltration of 22 distinct immune cell types in CKD. Western blotting, RT‐qPCR and HPA database were utilized to further validate the role of NFE2L2, NNMT and GDF15 in CKD.

By integrating bioinformatics including WGCNA, PPI, and GeneMANIA, 7 hub genes were identified including NNMT, GDF15, ACSL1, DLD, NFE2L2, PARP1, and NR4A1. These hub genes have been validated in the validation set and clinical correlation analysis established a clear link between hub gene expression and renal function deterioration. ROC analysis demonstrated excellent diagnostic efficacy. GSEA indicated that these hub genes affect CKD progress or prognosis through the posttranscriptional modifications and transport of pathogenic factors, immune dysfunction, and cell cycle dysregulation. The CKD samples exhibited elevated levels of CD8+ T cells and M0 macrophages, while memory B cells, resting memory CD4+ T cells, Tregs, and resting mast cells showed decreased levels. Moreover, in vitro experiments revealed that NFE2L2, NNMT and GDF15 were upregulated in TGF‐β1‐treated HK‐2 cells.

Our study confirms NNMT, GDF15, ACSL1, DLD, NFE2L2, PARP1, and NR4A1 as significantly upregulated biomarkers associated with ferroptosis in CKD progression, suggesting their potential as novel targets for CKD diagnosis and treatment.

## Linked entities

- **Genes:** NNMT (nicotinamide N-methyltransferase) [NCBI Gene 4837], GDF15 (growth differentiation factor 15) [NCBI Gene 9518], ACSL1 (acyl-CoA synthetase long chain family member 1) [NCBI Gene 2180], DLD (dihydrolipoamide dehydrogenase) [NCBI Gene 1738], NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780], PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142], NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164]
- **Diseases:** chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Genes:** HBA1 (hemoglobin subunit alpha 1) [NCBI Gene 3039] {aka ECYT7, HBA-T3, HBH, METHBA}, CXCR6 (C-X-C motif chemokine receptor 6) [NCBI Gene 10663] {aka BONZO, CD186, CDw186, STRL33, TYMSTR}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, KL (klotho) [NCBI Gene 9365] {aka HFTC3, KLA}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, DSCAM (DS cell adhesion molecule) [NCBI Gene 1826] {aka CHD2, CHD2-42, CHD2-52}, ACSL4 (acyl-CoA synthetase long chain family member 4) [NCBI Gene 2182] {aka ACS4, FACL4, LACS4, MRX63, MRX68, XLID63}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, SELENOS (selenoprotein S) [NCBI Gene 55829] {aka AD-015, ADO15, SBBI8, SELS, SEPS1, VIMP}, DLD (dihydrolipoamide dehydrogenase) [NCBI Gene 1738] {aka DLDD, DLDH, E3, GCSL, LAD, OGDC-E3}, GDF15 (growth differentiation factor 15) [NCBI Gene 9518] {aka GDF-15, HG, MIC-1, MIC1, NAG-1, PDF}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, NNMT (nicotinamide N-methyltransferase) [NCBI Gene 4837], CCN2 (cellular communication network factor 2) [NCBI Gene 1490] {aka CTGF, HCS24, IBP-8, IGFBP8, KMD, NOV2}, ACSL1 (acyl-CoA synthetase long chain family member 1) [NCBI Gene 2180] {aka ACS1, FACL1, FACL2, LACS, LACS1, LACS2}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, MECP2 (methyl-CpG binding protein 2) [NCBI Gene 4204] {aka AUTSX3, MRX16, MRX79, MRXS13, MRXSL, PPMX}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, KDM3B (lysine demethylase 3B) [NCBI Gene 51780] {aka 5qNCA, C5orf7, DIJOS, JMJD1B, NET22}, HAVCR1 (hepatitis A virus cellular receptor 1) [NCBI Gene 26762] {aka CD365, HAVCR, HAVCR-1, KIM-1, KIM1, TIM}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, CXCL16 (C-X-C motif chemokine ligand 16) [NCBI Gene 58191] {aka CXCLG16, SR-PSOX, SRPSOX}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}, TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, MIR130A (microRNA 130a) [NCBI Gene 406919] {aka MIRN130A, miRNA130A, mir-130a}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TSC22D3 (TSC22 domain family member 3) [NCBI Gene 1831] {aka DIP, DSIPI, GILZ, TSC-22R}
- **Diseases:** immune dysregulation (OMIM:614878), diabetic kidney disease (MESH:D003928), kidney (MESH:D007674), inflammatory cytokines (MESH:D000080424), ESRD (MESH:D007676), immune (MESH:D007154), infection (MESH:D007239), ischemia reperfusion injury (MESH:D015427), thrombosis (MESH:D013927), microvascular injury (MESH:D017566), glomerulosclerosis (MESH:D005921), atherosclerosis (MESH:D050197), decline of kidney function (MESH:D007680), metabolic disorders (MESH:D008659), ischemia (MESH:D007511), hypoxia (MESH:D000860), hemolytic (MESH:D006461), obesity (MESH:D009765), acute and chronic nephritis (MESH:C564356), Renal Function (MESH:D058186), cachexia (MESH:D002100), tubular injury (MESH:D000230), cancer (MESH:D009369), nonalcoholic fatty liver disease (MESH:D065626), tubular atrophy (MESH:D001284), CKD (MESH:D051436), fibrosis (MESH:D005355), inflammation (MESH:D007249), degenerative diseases (MESH:D019636), injury (MESH:D014947), mitochondrial dysfunction (MESH:D028361)
- **Chemicals:** PVDF (MESH:C024865), tryptophan (MESH:D014364), NAD+ (MESH:D009243), ROS (MESH:D017382), creatinine (MESH:D003404), CO2 (MESH:D002245), lipid (MESH:D008055), fatty acid (MESH:D005227), DMEM-F12 (-), penicillin (MESH:D010406), NAM (MESH:D009536), iron (MESH:D007501), streptomycin (MESH:D013307), methionine (MESH:D008715)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12933257/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12933257/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC12933257/full.md

---
Source: https://tomesphere.com/paper/PMC12933257